The promising results from ETA-selective atrasentan treatment in diabetic nephropathy patients, as shown in the SONAR trial and sparsentan (a combination of ETA-selective ERA and angiotensin II type 1 receptor antagonist) treatment for focal segmental glomerulosclerosis (FSGS) in the DUET trial, suggests that kidney-disease-related systemic arterial hypertension could also be an area where ERA and other endothelin-targeting treatments could be beneficial in the near future [76,181]. The gene discussed is AGTR1; the disease is focal segmental glomerulosclerosis.